Recombinant snake antivenoms get closer to the clinic

Andreas H. Laustsen

doi:10.1016/j.it.2024.03.001

Recombinant snake antivenoms get closer to the clinic

Andreas H. Laustsen^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

13 Downloads (Pure)

Abstract

Snakebite envenomings kill ~100 000 victims each year and leave many more with permanent sequelae. Antivenoms have been available for more than 125 years but are in need of innovation. A new study by Khalek et al. highlights broadly neutralizing human monoclonal antibodies (mAbs) that might be used to develop recombinant antivenoms with superior therapeutic benefits.

Original language	English
Journal	Trends in Immunology
Volume	45
Issue number	4
Pages (from-to)	225-227
ISSN	1471-4906
DOIs	https://doi.org/10.1016/j.it.2024.03.001
Publication status	Published - 2024

Access to Document

10.1016/j.it.2024.03.001Licence: CC BY

FulltextFinal published version, 468 KBLicence: CC BY

OpenUrl availability

Full text

Cite this

@article{dfa9a1b96dcb48439b2f418e8dc8bc77,

title = "Recombinant snake antivenoms get closer to the clinic",

abstract = "Snakebite envenomings kill ~100 000 victims each year and leave many more with permanent sequelae. Antivenoms have been available for more than 125 years but are in need of innovation. A new study by Khalek et al. highlights broadly neutralizing human monoclonal antibodies (mAbs) that might be used to develop recombinant antivenoms with superior therapeutic benefits.",

author = "Laustsen, {Andreas H.}",

year = "2024",

doi = "10.1016/j.it.2024.03.001",

language = "English",

volume = "45",

pages = "225--227",

journal = "Trends in Immunology",

issn = "1471-4906",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Recombinant snake antivenoms get closer to the clinic

AU - Laustsen, Andreas H.

PY - 2024

Y1 - 2024

N2 - Snakebite envenomings kill ~100 000 victims each year and leave many more with permanent sequelae. Antivenoms have been available for more than 125 years but are in need of innovation. A new study by Khalek et al. highlights broadly neutralizing human monoclonal antibodies (mAbs) that might be used to develop recombinant antivenoms with superior therapeutic benefits.

AB - Snakebite envenomings kill ~100 000 victims each year and leave many more with permanent sequelae. Antivenoms have been available for more than 125 years but are in need of innovation. A new study by Khalek et al. highlights broadly neutralizing human monoclonal antibodies (mAbs) that might be used to develop recombinant antivenoms with superior therapeutic benefits.

U2 - 10.1016/j.it.2024.03.001

DO - 10.1016/j.it.2024.03.001

M3 - Journal article

C2 - 38538486

SN - 1471-4906

VL - 45

SP - 225

EP - 227

JO - Trends in Immunology

JF - Trends in Immunology

IS - 4

ER -

Recombinant snake antivenoms get closer to the clinic

Abstract

Access to Document

OpenUrl availability

Fingerprint

Cite this